Company intelligence / Profile preview
Claris Bio
Jersey City, New Jersey, United Statesclarisbio.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Currently investigating the safety and efficacy of its topical ocular biologic dHGF in a randomized, controlled, double-masked study (CSB-C20-003, NCT04909450) in patients with stage 2 and 3 neurotrophic keratitis. Late-stage data was expected in the first half of 2024.
- Therapeutic areas
- Ophthalmology
- Modalities
- Recombinant protein
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Kringle PharmaMassachusetts Eye and Ear Infirmary (MEEI)
Beyond the preview
Go deeper on Claris Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Claris Bio.